Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Guido Ludergnani

Child & Adolescent Psychiatry Pensacola, FL Medical Doctor

NPI 1407990856 CMS profile 200288

1221 W Lakeview Ave, Pensacola, FL 32501

Open in the dashboard

General payments

$4,317

221 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Guido Ludergnani of Pensacola, FL is reported in the CMS Open Payments database as having received $4,317 across 221 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Child & Adolescent Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,039 38
2024 General $970 46
2023 General $793 39
2022 General $413 27
2021 General $262 17
2020 General $188 13
2019 General $653 41

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Guido Ludergnani
  • Child & Adolescent Psychiatry median
  • Middle half of Child & Adolescent Psychiatry
  • National median

In program year 2025, general payments to Guido Ludergnani were reported at $1,039. Among 1,601 Child & Adolescent Psychiatry profiles paid that year, the median was $132 and the middle half received between $41 and $474.

Show as a table
Year Guido Ludergnani Child & Adolescent Psychiatry median Middle half National median
2019 $653 $129 $42–$419 $163
2020 $188 $81 $28–$226 $114
2021 $262 $115 $31–$326 $132
2022 $413 $124 $40–$382 $149
2023 $793 $130 $45–$420 $160
2024 $970 $141 $42–$490 $164
2025 $1,039 $132 $41–$474 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Neurocrine Biosciences, Inc. $728 24 payments
  2. Janssen Pharmaceuticals, Inc $660 32 payments
  3. Supernus Pharmaceuticals, Inc. $559 34 payments
  4. Sunovion Pharmaceuticals Inc. $374 27 payments
  5. Corium, Inc. $285 15 payments
  6. Tris Pharma Inc $276 16 payments
  7. Ironshore Pharmaceuticals Inc. $252 15 payments
  8. Otsuka America Pharmaceutical, Inc. $215 11 payments
  9. Teva Pharmaceuticals USA, Inc. $136 8 payments
  10. E.R. Squibb & Sons, L.L.C. $136 4 payments
  11. Other $697 35 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,317 221 payments
Products named General payments · program years 2019–2025
  1. INGREZZA $711 23 payments
  2. INVEGA SUSTENNA $418 21 payments
  3. INVEGA TRINZA $418 21 payments
  4. QELBREE Psychology $375 28 payments
  5. LATUDA $374 27 payments
  6. Azstarys $268 14 payments
  7. SPRAVATO $254 12 payments
  8. Qelbree Viloxazine Hydrochloride $184 6 payments
  9. REXULTI $156 8 payments
  10. ABILIFY MAINTENA $148 7 payments
  11. Other $2,154 110 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

12

Median for Psychiatry: 574

Drug cost

$254

Median for Psychiatry: $27,624

Branded share of claims

100%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Guanfacine Hcl Er Guanfacine Hcl Brand 12 $254

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$2,612

Medicare's payments for the services billed

Medicare patients

26

Average age 60

Services billed

53

13 women, 13 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 58%
Depression 58%
Osteoporosis 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qelbree
  • Supernus Pharmaceuticals, Inc. $170
$170 — —
INVEGA SUSTENNA
  • Janssen Pharmaceuticals, Inc $143
$143 — —
INVEGA TRINZA
  • Janssen Pharmaceuticals, Inc $143
$143 — —
JORNAY PM
  • Ironshore Pharmaceuticals Inc. $66
$66 — —
FANAPT
  • Vanda Pharmaceuticals Inc. $56
$56 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

221 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record